Aclaris Therapeutics ACRS Drug Candidate Ati2138 — Research And Development Project Spend
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept acrs:ResearchAndDevelopmentProjectSpend.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's drug candidate ati2138 — research and development project spend.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's drug candidate ati2138 — research and development project spend?
- Aclaris Therapeutics (ACRS) reported drug candidate ati2138 — research and development project spend of $491K in Q1 2026.
- How has Aclaris Therapeutics's drug candidate ati2138 — research and development project spend changed year-over-year?
- Aclaris Therapeutics's drug candidate ati2138 — research and development project spend decreased by 72.8% year-over-year, from $1.81M to $491K.
- What is the long-term trend for Aclaris Therapeutics's drug candidate ati2138 — research and development project spend?
- Over 2 years (2023 to 2025), Aclaris Therapeutics's drug candidate ati2138 — research and development project spend has grown at a -36.3% compound annual growth rate (CAGR), from $12.14M to $4.92M.
- What does drug candidate ati2138 — research and development project spend mean?
- This metric represents the total direct costs and allocated resources dedicated to the research and development activities of a specific clinical-stage drug candidate. It captures the capital intensity and investment priority assigned to advancing a particular therapeutic asset through the drug development pipeline. Tracking this spend helps investors assess the company's commitment to specific immuno-inflammatory programs and the potential for future clinical milestones.